GUILFORD, Conn. / Mar 24, 2023 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation, Virtual Conference to be held on Thursday, April 6, 2023.
Patrick Schneider, Ph.D., Quantum-Si’s President and Chief Operating Officer, will participate in the panel discussion “How to Translate Insights from Proteomics and Advances in AI into Drug Discovery and Innovation?” at 10:30 AM ET.
Additionally, Jeff Hawkins, Quantum-Si’s Chief Executive Officer, and Dr. Schneider will participate in a fireside chat at 2:30 PM ET.
A link for live and archived webcasts of both events will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing CompanyTM, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.
| Last Trade: | US$1.27 |
| Daily Change: | 0.05 4.10 |
| Daily Volume: | 5,478,191 |
| Market Cap: | US$248.350M |
November 20, 2025 November 05, 2025 September 23, 2025 September 08, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load